Serum Institute of India (SII) | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Saturday
June 14, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SATURDAY, JUNE 14, 2025

Serum Institute of India (SII)

Adar Poonawalla, Chief Executive Officer (CEO) of the Serum Institute of India poses for a picture at the Serum Institute of India, Pune, India, 30 November 2020. REUTERS/Francis Mascarenhas
South Asia

India develops its first cervical cancer vaccine

Photo :UNB
Global Economy

Indian vaccine giant Serum plans African plant in global expansion

Adar PoonawallaPhotographer: Dhiraj Singh/Bloomberg
Coronavirus chronicle

Omicron-specific booster shot possible: SII CEO Adar Poonawalla

Serum Institute to resume supply of Covishield to Covax: Reports
Coronavirus chronicle

Serum Institute to resume supply of Covishield to Covax: Reports

A woman reacts as she receives a dose of the COVISHIELD vaccine, a coronavirus disease (COVID-19) vaccine manufactured by Serum Institute of India, in an alley at a slum area in Ahmedabad, India, September 28, 2021. REUTERS/Amit Dave
South Asia

India rules out reducing gap between Covishield doses

Students wearing protective face masks attend their class as they maintain social distancing after authorities reopened schools for classes for 10 and 12 after the schools were closed for months due to the coronavirus disease (COVID-19) outbreak, in Ahmedabad, India, January 11, 2021. REUTERS/Amit Dave/File Photo
Coronavirus chronicle

India allows Serum Institute to enrol 7-11 year olds in Novavax Covid-19 vaccine trial

A medical worker displays a vial with a coronavirus disease (Covid-19) vaccine at a vaccination centre in Tehran, Iran Sept 20, 2021. Majid Asgaripour/REUTERS
Coronavirus chronicle

India's Serum Institute to invest $68 million in UK vaccine maker Oxford Biomedica

Indian High Commissioner to Bangladesh Vikram Kumar Doraiswami. Photo: Collected
Covid-19 in Bangladesh

Bangladesh to get vaccines from India soon: Doraiswami

SII must return money if they fail to deliver vaccines: Health minister
Bangladesh

SII must return money if they fail to deliver vaccines: Health minister

Serum Institute of India to manufacture Sputnik V starting September
World+Biz

Serum Institute of India to manufacture Sputnik V starting September

A health official draws a dose of the AstraZeneca's Covid-19 vaccine manufactured by the Serum Institute of India, at Infectious Diseases Hospital in Colombo, Sri Lanka Jan 29, 2021. REUTERS/FILE
Coronavirus chronicle

India raises Covid vaccine production amid sharp dip in cases

FILE PHOTO: Vials of AstraZeneca's COVISHIELD, coronavirus disease (Covid-19) vaccine, are seen before they are packaged inside a lab at Serum Institute of India, Pune, India, Nov. 30, 2020. REUTERS/Francis Mascarenhas/File Photo
Coronavirus chronicle

SII seeks EU travel approval for its Covishield vaccine

Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Novavax logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo
Coronavirus chronicle

SII to introduce Novavax vaccine in India by September

  • Show More
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net